INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indo US Bio-Tech Limited has submitted its standalone unaudited financial results for the quarter ended June 30, 2025, approved by the Board of Directors on August 12, 2025. The results were also reviewed by the Audit Committee. Gautam N Associates, Chartered Accountants issued a clean (unqualified) limited review report, stating nothing came to their attention suggesting material misstatement in the results. The document is heavily garbled by OCR, so specific revenue, expense, and profit figures could not be reliably extracted. The filing is routine, complying with SEBI Listing Regulations 30 and 33, and the results have been uploaded on the company's website.
Routine quarterly results submission with a clean auditor's review report — no negative flags raised. Shareholders should refer to the actual results document on the company website for precise financial numbers, as the OCR quality of this filing prevents detailed number-level commentary.